Pharmaceutical peptides for the treatment of inflammatory diseases

The CKRD peptide or peptidic compound according to claim 4 wherein one or more amino acids are a steric enantiomer (D isomer), a rare amino acid of plant origin, an unnatural amino acid or amino acid mimetic, or have been modified by any one or more modifications selected from acetylation, acylation, phosporylation, dephosphorylation, glycosylation, myristollation, amidation, aspartic acid/asparagine hydroxylation, phosphopantethane attachment, methylation, methylthiolation, prensyl group attachment, intein N-/C-terminal splicing, ADP-ribosylation, bromination, citrullination, deamination, dihydroxylation, formylation, geranyl-geranilation, glycation, and palmitoylation.

The peptide or peptidic compound of claim 7 wherein said at least 6 amino acids maintain their relative positions as they appear in WVFGSGLCK (SEQ ID NO:

• 16), over the span of 9 amino acids.

A method for identifying CKRD peptides or peptidic compounds comprising:

• selecting a candidate peptide containing from about 3 to about 25 amino acids derived from a chemokine receptor regulatory domain;
• and determining the ability of the candidate peptide to modulate the activity of disease-related chemokines.